期刊文献+

专利保护和公共健康:国家药物政策中的冲突与协调

Patent Protection and Public Health: Conflict and Coordination in the National Medicine Policy
原文传递
导出
摘要 药物专利保护能够有效地激励科技创新,然而,产业资本寻求利益最大化导致了产业资本诉求与公共健康问题无法避免的利益冲突,专利保护对于药物可及性的影响十分明显,两者的冲突只能进一步协调而不可能完全消失。在一个合理的专利制度体系下,会不断激励药物研发创新、改善人类生活质量。国家药物政策的一个重要作用就是通过协调机制增强药物的可及性。 Medical patents protection can effectively encourage medicine research and innovation. However, there is a clearly defined income boundary by the property right during the process that industrial capital maximize its interests. This leds to an inevitable conflicts of interest between the industry capital' s appeal for value and the issue of public health. Patent protection for medicine has an obvious influence on the accessibility of medicine. The conflicts only can be coordinated and cannot disappear entirely. The national medicine policy plays an important role on increasing accessibility under the patent system through coordination mechanism.
作者 葛锐 尹爱田
出处 《中国卫生经济》 北大核心 2013年第5期19-22,共4页 Chinese Health Economics
基金 国家社科基金项目(11CGL096) 山东省自然科学基金项目(ZR2010GL006)
关键词 专利保护 公众健康 国家药物政策 patent protection public health national medicine policy
  • 相关文献

参考文献11

  • 1Arrow K J.Economic welfare and the allocation on resourcesfor invention[R].Nelson: The Rate and Direction of InventiveActivity,NBER.Princeton, 1962.
  • 2Mansfield E, Schwartz M, Wagner S.Imaitation, costs andpatents: an empirical study[J].The Economic Journal, 1981,12(91):907-918.
  • 3Mansfield E.How rapidly dose new industrial technology leakout?[J].Journal of Industrial Economics, 1985 , 12(34):217-223.
  • 4Henderson R,Cockbum I.Scale, scope and spi Hover: thedeterminants of research productivity in drug discovery [J].Rand Journal of Economics, 1996, 27 (1):35-37.
  • 5Pharmaceutical Research and Manufacturers of America.Drugdiscovery and development: understanding the R&D process[R].Washimyton DC:Pharmaceutical Research and Manufac-turers of America, 2007.
  • 6DiMasi J A, Grahowski H G.The cost of biopharmaceuticalR&D: Is biotech different? [J].Managerial and DecisionEconomics, 2007(28):469-479.
  • 7Grabowski H, Vernon J, DiMasi J.Returns on research anddevelopment for 1990s new drug introductions[J].Pharma-coeco-momics, 2002,(20)3:11-29.
  • 8刘莹,梁毅.论药品可及性与药品专利保护[J].中国药房,2007,18(13):966-968. 被引量:13
  • 9Grabowski H, Vernon J.Longer patents for increased genericcompetition in the US: the waxman-hatch act after one decade[J].Pharmacoeconornics, I996,10(SuppI 2):110-23.
  • 10Nordhaus W D.Invetion, growth, and welfare: a theoreticaltreament of tecnological change[M].The USA: The MIT, 1969.

二级参考文献4

  • 1[1]WHO Medicines Strategy.Framework for Action in Essential Drugs and Medicine Policy 2000~2003[M].Geneva,Switzerland,2001:315~317.
  • 2[3]Michael Kremer.Pharmaceuticals and the developing world[J].Journal of Economics Perspectives,2002,16(4),206.
  • 3[5]WHO.与贸易有关的知识产权、药品和公共健康:问题和建议[EB/OL].http://www.twnchinese.org.my/iprs/intellectual2/index.html.
  • 4[6]MSF.Drug patents under the spotlight:sharing practical knowledge about pharmaceutical patents[EB/OL].http://www.msf.org/about/index.cfm.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部